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INTRODUCTION 
Prolonging therapeutic levels of a drug within the vitreous 
to treat blinding diseases is one of the most important goals 
in ophthalmic drug development. Intravitreal (IVT) inject-
tions of therapeutic proteins and the use of steroid implants 
in the vitreous are currently the best clinical methods to 
achieve prolonged exposure in the back of the eye. Thera-
peutic biologics registered for ophthalmic use by intravitre-
al (IVT) injection comprise a PEGylated-aptamer (Pegap-
tanib), antibody fragment (ranibizumab), and an Fc fusion 
(alfibercept). The monoclonal antibody, bevacizumab is 
also widely used as an unlicensed medicine to treat age 
related macular degeneration. It is anticipated that ophthal-
mic protein-based medicines, which tend to be potent and 
have a rapid onset of action, will continue to be developed 
as molecular mechanisms involved in blinding diseases 
become better understood 
Mass exchange within the eye is dominated by 
aqueous which is secreted at 2.0–2.5 µL/min into the 
vitreous from the ciliary body. The majority of aqueous 
passes the anterior hyaloid membrane and flows into the 
anterior chamber to exit the eye via trabecular and 
uveoscleral pathways. There are two main drug elimination 
pathways from the vitreous: (a) the aqueous outflow into 
the anterior chamber and (b) permeation through the retina 
via retinal-choroid-sclera (RCS) pathways. As high 
molecular weight and charged molecules, therapeutic 
proteins clear predominantly through the anterior route. 
Proteins have been reported to have longer half-lives (i.e. 
days) in the vitreous than soluble RCS permeable molecules 
(e.g. lipophilic molecules), which generally clear in a 
matter of hours. 
There is much research focused on developing 
new strategies to increase the vitreous residence times of 
macromolecular drugs to avoid the frequency of IVT 
injections. We have developed1 and validated a two-
compartment, aqueous outflow model to be used for ocular 
drug development called the PK-Eye. It has been shown to 
be particularly useful in evaluating protein PK and stability 
properties. Our model is used to aid the preclinical 
development of novel, long-acting therapies. As more 
stable protein therapeutics are developed, much higher 
concentration doses may be possible where exploitation of a 
therapeutic tail is difficult to evaluate in animal models 
because of the generation of anti-drug antibodies (ADAs). 
The less frequent dosing of aflibercept is primarily based on 
using a larger dose than what is used for ranibizumab.  
In this study, we studied the different doses of 
bevacizumab (1.25, 2.5 and 5.0 mg) in the PK-Eye (Figure 
1) with phosphate buffer saline (PBS, pH 7.4) and 
simulated vitreous (polymeric combination of hyaluronic 
acid and agar) to explore the protein’s therapeutic tail.  
 
Figure 1: The PK-Eye model comprises two plastic pieces that are 
held together with four screws with a fitted rubber washer (7) 
between the two pieces to seal the posterior cavity and to prevent 
leakage. A membrane (3) separates the anterior (1) and posterior 
(2) cavities, which have a volume of 200 µL and 4.2 mL, 
respectively. The inlet port (4) allows flow immediately posterior 
to the membrane (3). The inlet port was connected with plastic 
tubing (1.5mminternal diameter) to a 16-channel Ismatec 
peristaltic pump to produce a flow rate of 2.0 µL/min of PBS, pH 
7.4 with 0.02% sodium azide. Aqueous outflow is collected from 
the anterior cavity at a single outlet port (5), which is elevated to 
about 3.0 cm to provide a small amount of back-pressure to 
maintain a full internal volume within the model. The inner 
diameter of the inlet and outlet ports was 1.0–1.5 mm.1 
METHOD 
The PK-Eye has been designed to have both an anterior (0.2 
mL) and a posterior (4.2 mL) cavity with a membrane in 
between the two cavities. There is an inlet port that allows 
phosphate buffered saline (PBS, pH 7.4) to flow at a fixed 
rate of 2.0 µL/min at ambient temperature. The posterior 
cavity of the model was filled with either PBS, pH 7.4 or 
simulated vitreous, which comprised a combination of 
hyaluronic acid and agar. The combination of agar and 
hyaluronic acid has been found to have a dynamic viscosity 
of 0.6 Pa.s (average human vitreous viscosity is around 0.5 
Pa.s). Bevacizumab (25 mg/mL) was injected via the 
injection port into the posterior cavity at different doses 
(1.25 mg in 50 µL; 2.5 mg in 100 µL and 5.0 mg in 200 
µL). Samples were obtained from the anterior outflow 
sampling port at various time intervals and were analysed 
by high performance liquid chromatography (HPLC) at 280 
nm to determine their clearance kinetics. Experiments were 
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conducted in triplicate (n=3) and results were plotted in 
OriginPro with their means and standard deviations (± 
STD). The rate constant (k) and half-life (t1/2) were 
calculated from the best fitting model with the data set.  
RESULTS 
Clinically, the therapeutic dose of bevacizumab is usually 
1.25 m, in a 50 µL injection. When this dose was tested in 
the PK-Eye containing PBS (to mimic vitrectomised eyes) 
and simulated vitreous, the half-lives (t1/2) for the residence 
times in the model were 1.2 ± 0.1 days and 10.1 ± 0.7 days 
respectively. These half-lives are comparable to what is 
observed in vitrectomised monkey eyes and human eyes. 
CONCLUSION 
The model is currently being used to study the stability of 
proteins to develop strategies to maintain the presence of 
the protein in the posterior cavity for longer periods, e.g. in 
the form of implants and sustained release formulations. 
The PK-Eye can easily be used to evaluate protein function 
and stability. This is difficult to impossible to accomplish 
using animal models and is especially important for dosage 
forms that have longer clearance times that could extend 
over a 2–3-month period. Our studies show the PK-Eye 
model has many of the features needed to become a 
practical in vitro model with the capacity to contribute to 
research efforts focused on the development of new protein 
therapeutics. 
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Figure 2: Different doses of bevacizumab (2.5 mg and 5.0 mg) tested in the PK-Eye after injection into the posterior cavity of the PK-Eye 
containing PBS, pH 7.4 (A and A1) and simulated vitreous (B and B1). All data were obtained in triplicate (n=3) and were plotted as the 
mean and standard deviation (± STD). 
 (6.7–10.0 days)2–5. Larger doses (2.5 and 5.0 mg) of 
bevacizumab were then evaluated using PBS in the model, 
and the half-lives were 2.3 ± 0.8 and 3.4 ± 0.7 days 
respectively Figure 2 (A and A1). With simulated vitreous, 
the 2.5 and 5.0 mg doses displayed half-lives of 
approximately 15.4 ± 0.7 and 18.3 ± 1.1 days respectively 
(Figure 2, B and B1).  Larger doses increased the clearance 
to a moderate extent, as would be expected with aflibercept 
(~115 kDa, 2.0 mg). Pegaptanib (~50 kDa, 0.3 mg) 
displayed a half-life in humans of about 7-8 days, which 
increased to 10 ± 4 days using a 3.0 mg dose. 
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